Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81442-noonan-spectrum-disorder-genomic-panel
    Ask Trek AI about this page

    CPT 81442: Genomic Panel for Noonan‑Spectrum Disorders

    Commercial payers pay $1843 on average nationally for this procedure.

    CPT code 81442 describes a genomic sequence analysis panel performed on a patient specimen to evaluate genetic sequences of at least 12 genes associated with Noonan-spectrum disorders (NSD); the service is a molecular diagnostic genomic sequencing panel typically performed in a clinical molecular laboratory or reference diagnostic laboratory and ordered for pediatric patients with developmental abnormalities such as congenital heart defects and characteristic craniofacial or skin findings.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 81442 policy alerts

    Get alerted when payer policies referencing 81442 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial pricing for CPT 81442 centers around BUCA’s average commercial mean of $1,842.90, with individual payer means clustered above and below that mark. Blue Cross Blue Shield’s mean of $2,192.40 and Cigna’s mean of $2,009.00 sit above BUCA, while Aetna ($1,056.70) and UnitedHealth Group ($1,414.30) fall below. Maximums vary widely for some payers (e.g., Cigna $6,430.50, UnitedHealth Group $6,433.40, Blue Cross Blue Shield $6,254.00), reflecting occasional high negotiated rates but are not the primary focus for typical commercial activity.

    Dispersion measured as the interquartile range (P75 minus P25) highlights how concentrated typical reimbursements are: Aetna has a range of $1,129.00, Blue Cross Blue Shield $980.30, BUCA $1,082.70, Cigna $1,544.00, and UnitedHealth Group $815.00. That makes UnitedHealth Group the tightest among these payers (IQR $815.00) and Cigna the widest (IQR $1,544.00), with BUCA’s IQR ($1,082.70) indicating moderate spread around its mean commercial rate.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 6-year-old child is referred by a pediatric cardiologist and a clinical geneticist for molecular testing after presenting with congenital heart defects (pulmonic valve stenosis), short stature, and distinctive facial features suggestive of a Noonan‑spectrum disorder (NSD). A peripheral blood specimen is collected in an appropriate EDTA tube and sent to a clinical molecular pathology laboratory. The laboratory performs DNA extraction, next‑generation sequencing of a targeted multi‑gene panel covering at least 12 genes associated with NSD, bioinformatic alignment and variant calling, and clinical interpretation including variant classification. A laboratory analyst documents analytic methods and quality metrics; a molecular pathologist reviews and signs out the interpretive report. Results are returned to the ordering pediatrician and genetic counselor for family discussion and cascade testing if a pathogenic or likely pathogenic variant is identified.

    Typical site of service: outpatient specialty clinic or ambulatory phlebotomy with testing performed in a clinical molecular diagnostic laboratory. Typical payer interactions include private insurers such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for medically necessary testing.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81440Genomic sequence analysis panel to evaluate at least 100 mitochondrial genes related to nerve or muscle pathologiesDifferent targeted panel; billed when mitochondrial gene sequencing is ordered instead of or in addition to the NSD panel for alternate clinical indications.

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207ZP0102X
    207ZP0105X
    207Q00000X
    2278G0305X
    261QA0600X
    2471C3401X
    281P00000X
    332BC3200X

    Related ICD-10-CM Codes

    28 rows

    ICD-10-CM CodeDescription
    C18.9Malignant neoplasm of colon, unspecified
    C25.9Malignant neoplasm of pancreas, unspecified
    C34.90Malignant neoplasm of unspecified part of unspecified bronchus or lung
    C50.919Malignant neoplasm of unspecified site of unspecified female breast
    C61Malignant neoplasm of prostate
    E34.9Endocrine disorder, unspecified
    E85.9Amyloidosis, unspecified
    F80.2Mixed receptive-expressive language disorder
    F82Specific developmental disorder of motor function
    M31.0Hypersensitivity angiitis

    Showing 1–10 of 28

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81417-EXOME-SEQUENCE-REEVALUATION

    CPT 81417: Exome Reanalysis for New Clinical Information

    CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    81441Genomic sequence analysis panel of at least 30 genes for inherited bone marrow failure syndromes (IBMFS)Alternative disease‑specific panel billed when hematologic or bone marrow failure phenotypes are the clinical concern rather than NSD.
    81443Genomic sequence analysis panel of at least 15 genes related to severe inherited conditions, many in Ashkenazi Jewish descentAlternative multi‑gene panel for a different spectrum of inherited conditions; may be performed when differential diagnosis includes syndromes covered by that panel.
    81445Genomic sequence analysis panel of 5‑50 genes in solid organ neoplasms, DNA and possibly RNA alterationsDifferent oncology‑focused panel used when tumor profiling is indicated; distinct from germline NSD testing but may be performed in parallel if cancer predisposition is a concern.